

## Availability of the 2022 Universal Registration Document, including the Annual Financial Report

**Paris – April 14, 2023** – EUROAPI announces the publication of its 2022 Universal Registration Document, approved by the French *Autorité des marchés financiers* (AMF) on April 13, 2023, under number R.23-009.

The 2022 Universal Registration Document includes in particular:

- The annual financial report;
- The Board of Directors' corporate governance report;
- The information about social, environmental, and societal responsibility (including the extra-financial performance declaration);
- the statutory auditors reports;
- The disclosures relating to statutory auditors' fees; and
- The description of the share buy-back program.

This document is available on EUROAPI's website: <https://www.euroapi.com/en/investors/regulatory-information/financial-reports> and on the AMF website ([www.amf-france.org](http://www.amf-france.org)). The document is made available to the public under the conditions provided by the regulations in force.

### About EUROAPI

EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers' and patients' needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies, while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.

Taking action for health by enabling access to essential therapies inspires our 3,450 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris (Ticker: EAPI – ISIN: FR0014008VX5). Find out more at [www.euroapi.com](http://www.euroapi.com) and follow us on [LinkedIn](#)

---

**Media Relations Contact:**

Laurence Bollack  
Mob.: +33 (0)6 81 86 80 19  
mr@euroapi.com

**Investor Relations Contact:**

Sophie Palliez-Capian  
Mob.: +33 (0)6 87 89 33 51  
ir@euroapi.com

**Forward-Looking Statements**

*Certain information contained in this press release is forward looking and not historical data. These forward-looking statements are based on opinions, projections and current assumptions including, but not limited to, assumptions concerning the Group's current and future strategy, financial and non-financial future results and the environment in which the Group operates, as well as events, operations, future services or product development and potential. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Forward looking statements and information do not constitute guarantees of future performances, and are subject to known or unknown risks, uncertainties and other factors, a large number of which are difficult to predict and generally outside the control of the Group, which could cause actual results, performances or achievements, or the results of the sector or other events, to differ materially from those described or suggested by these forward-looking statements. These risks and uncertainties include those that are indicated and detailed in Chapter 3 "Risk factors relating to the issuer" of the prospectus approved by the French Financial Markets Authority (Autorité des marchés financiers, AMF) on March 31, 2022, under number 22-076. These forward-looking statements are given only as of the date of this press release and the Group expressly declines any obligation or commitment to publish updates or corrections of the forward-looking statements included in this press release in order to reflect any change affecting the forecasts or events, conditions or circumstances on which these forward-looking statements are based.*